Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Timothy, Qi"'
Autor:
Xiaoling Qiang, Weiqiang Chen, Cassie Shu Zhu, Jianhua Li, Timothy Qi, Li Lou, Ping Wang, Kevin J. Tracey, Haichao Wang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The pathogenic mechanisms of bacterial infections and resultant sepsis are partly attributed to dysregulated inflammatory responses sustained by some late-acting mediators including the procathepsin-L (pCTS-L). It was entirely unknown whether any com
Externí odkaz:
https://doaj.org/article/c8c00067772e467fad1081519e885c67
Autor:
Timothy Qi, Yanguang Cao
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 2, Pp 236-249 (2023)
Abstract Enrolling patients in immunotherapy clinical trials is becoming increasingly competitive. Virtual clinical trials can help investigators answer key questions despite this. For example, pembrolizumab is the recommended first‐line treatment
Externí odkaz:
https://doaj.org/article/925dd197b9954cd598191f39e478788d
Publikováno v:
eLife, Vol 12 (2023)
Effector T cells need to form immunological synapses (IS) with recognized target cells to elicit cytolytic effects. Facilitating IS formation is the principal pharmacological action of most T cell-based cancer immunotherapies. However, the dynamics o
Externí odkaz:
https://doaj.org/article/fb920c9a3f024b84b02064bb1718f605
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
RECISTv1.1 (Response Evaluation Criteria In Solid Tumors) is the most commonly used response grading criteria in early oncology trials. In this perspective, we argue that RECISTv1.1 is ambiguous regarding lesion-to-lesion variation that can introduce
Externí odkaz:
https://doaj.org/article/c6ca0f0cc1ec459093f9528bab1dc34f
Publikováno v:
PLoS Computational Biology, Vol 19, Iss 4, p e1010976 (2023)
Predator-prey theory is commonly used to describe tumor growth in the presence of selective pressure from the adaptive immune system. These interactions are mediated by the tumor immunopeptidome (what the tumor "shows" the body) and the T-cell recept
Externí odkaz:
https://doaj.org/article/9ca363d1889d46a0a7a505c2fd371ffb
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Despite the success in B-cell malignancies, chimeric antigen receptor (CAR)-T cell therapies have not yet demonstrated consistent efficacy across all patients and tumor types, particularly against solid tumors. Higher rates of T cell exhaustion are a
Externí odkaz:
https://doaj.org/article/d06a527cc53f4627ae9ea09a1f542fb5
Publikováno v:
PLoS Genetics, Vol 16, Iss 4, p e1008665 (2020)
Lipid droplets (LD) are affected in multiple human disorders. These highly dynamic organelles are involved in many cellular roles. While their intracellular dispersion is crucial to ensure their function and other organelles-contact, underlying mecha
Externí odkaz:
https://doaj.org/article/dddd12ae689347068de717598048fe3c
Publikováno v:
Pharm Res
Project Optimus is a US Food and Drug Administration (FDA) initiative to reform dose selection in oncology drug development. Here, we focus on tumor evolution, a broadly observed phenomenon that invariably leads to therapeutic failure and disease rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92617d49c499f6e1e2b036d497a99039
https://doi.org/10.1007/s11095-022-03380-1
https://doi.org/10.1007/s11095-022-03380-1
Autor:
Timothy Qi, Yanguang Cao
Publikováno v:
European Journal of Pharmaceutical Sciences. 186:106467
Background and Purpose: Despite their use to treat cancers with specific genetic aberrations, targeted therapies elicit heterogeneous responses. Sources of variability are critical to targeted therapy drug development, yet there exists no method to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0952c42842401c276cdaa2feb2248e38
https://doi.org/10.1016/j.ejps.2023.106467
https://doi.org/10.1016/j.ejps.2023.106467
Autor:
Timothy Qi, Yanguang Cao
Publikováno v:
CPT: pharmacometricssystems pharmacologyREFERENCES.
Enrolling patients in immunotherapy clinical trials is becoming increasingly competitive. Virtual clinical trials can help investigators answer key questions despite this. For example, pembrolizumab is the recommended first-line treatment for non-sma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad96377911c3be1ed32d32a41dbab7dd
https://pubmed.ncbi.nlm.nih.gov/36547213
https://pubmed.ncbi.nlm.nih.gov/36547213